Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores

뉴스 본문을 불러오고 있어요.

Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores | 웨이프 WAPE

Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores

기사 요약

관련 종목

댓글 —